Ovagen 20mg vial

NOT FOR HUMAN CONSUMPTION

Ovagen® is marketed in the “peptide bioregulator” ecosystem as a liver and gastrointestinal tract–directed peptide product. In many research/vendor descriptions, “Ovagen” is presented as an ultrashort tripeptide with the sequence Glu–Asp–Leu (EDL).

In product-line brochures, Ovagen is also described as a peptide complex (often labeled AC-3, “liver”), i.e., a mixture of short peptides intended to mimic natural peptide fractions.

Practical identity caveat (important): depending on the supplier, “Ovagen” may mean (a) the defined EDL tripeptide, or (b) a branded AC-3 peptide complex. For scientific writing, you should explicitly state which one you mean and require COA/MS/HPLC if discussing a specific molecule.

2) Biological rationale: why a liver/GI ultrashort peptide?

The bioregulator hypothesis (Khavinson-style) proposes that 2–4 amino-acid peptides can enter cells and influence gene expression programs in a tissue-biased manner, potentially via interactions with DNA/chromatin and transcriptional regulation.

For an acidic tripeptide like EDL (Glu/Asp-containing), the gene-regulation framework often emphasizes:

• physicochemical interactions of charged residues with nucleic acids (as a conceptual basis for DNA/chromatin effects), and

• downstream shifts in transcription programs relevant to cellular stress responses and repair.

3) Proposed molecular mechanism of action

3.1 “Pharmacodynamics” framing (non-receptor, gene-program modulation)

Unlike GLP-1 agonists or monoclonal antibodies, Ovagen/EDL is not framed as a ligand for a canonical receptor with a well-mapped signaling cascade. It is typically described as:

• capable of cell and nuclear penetration (general claim across bioregulators), and

• influencing transcription patterns that govern hepatocellular metabolism, antioxidant defense, and repair.

3.2 Downstream biology (hypothesis map)

Interpretation constraint: these are mechanistic hypotheses and positioning claims, not clinically proven therapeutic effects.

4) Pharmacokinetics and delivery constraints (what can be said responsibly)

There is no FDA/EMA drug label PK for Ovagen (EDL or AC-3). Key realities for ultrashort peptides:

• Rapid enzymatic degradation is typical without stabilization/formulation strategies.

• Exposure and effect are route/formulation dependent (capsule vs sublingual drops vs injectable “research peptide” are not interchangeable in any rigorous sense).

• Product brochures describe oral/sublingual “bioregulator” formats, but these do not substitute for formal PK/PD studies.

5) Evidence base: preclinical vs clinical

5.1 Mechanistic / preclinical (stronger, but still limited)

The strongest defensible foundation is the broader gene-expression bioregulator literature, which discusses ultrashort peptide–DNA interactions and transcriptional modulation mechanisms (framework-level, not Ovagen-specific clinical proof).

Some sources also describe Ovagen as being used in research on hepatocellular repair and antioxidant defense (again, positioning rather than a standardized clinical endpoint dataset).

5.2 Human clinical evidence (weaker / not drug-grade from accessible sources)

Branded brochures and commercial summaries claim benefits such as “normalization” of liver/GI function and support under stress/aging, but these materials generally do not present full RCT-grade methods and outcomes (randomization, blinding, prespecified endpoints, effect sizes, adverse event accounting).

6) Safety and tolerability (risk-based framing)

High-certainty statement: Ovagen (as sold in the bioregulator/research market) does not carry a drug-label–grade safety profile.

Main uncertainty drivers:

• Identity variability (EDL tripeptide vs AC-3 complex).

• Purity/contamination/sterility risks depending on supply chain and intended route (especially for “research peptide” vials).

• Off-target transcriptional effects are theoretically possible for agents proposed to modulate gene expression, this increases the importance of controlled trials before strong claims.

7) Regulatory landscape

Ovagen is typically marketed as a bioregulator peptide complex or research peptide, and is not an FDA/EMA-approved therapeutic with standardized indications.

8) Future directions (what would make Ovagen “clinical-grade”)

To validate Ovagen scientifically as a modern therapeutic concept, the decisive steps would be:

1. Molecule definition: separate “EDL” vs “AC-3 complex” with exact composition, stability, impurity profile.

2. Human PK/PD bridging: demonstrate systemic exposure (or local mucosal uptake) and target-engagement biomarkers (liver transcriptomic/stress markers).

3. Controlled trials: well-defined populations (e.g., NAFLD risk, drug-induced liver injury prevention contexts, etc.), with validated endpoints (ALT/AST trajectories, imaging biomarkers where relevant, symptom/QoL measures), and robust safety monitoring.

Selected references (most load-bearing)

• Ovagen positioned as liver/GI bioregulator; AC-3 complex (brochure PDF):

• Ovagen described as EDL (Glu–Asp–Leu) in multiple research/vendor summaries:

• Systematic review providing the broader ultrashort peptide gene-expression/DNA interaction framework:

• Example vendor description emphasizing hepatocellular repair/antioxidant gene modulation framing: